Atrium acquisitions boost revenues
This article was originally published in The Tan Sheet
Executive SummaryCanadian health and nutrition products manufacturer and marketer Atrium Innovations says acquisitions and organic sale growth drove a 15.5 percent increase in net revenues to $70.6 million in its 2009 first quarter. Atrium in January purchased probiotic firm Nutri-Health Supplements of Cottonwood, Ariz., and added German enzyme manufacturer Enzym-Arzneimittel-Berlin to its operations in late 2008 (1"The Tan Sheet" Jan. 12, 2009, In Brief). The Quebec City-based firm said May 12 that it anticipates increasing U.S. sales of Wobenzym N enzyme support formula, which is approved for sale at Whole Foods. Net earnings during the January-March period from continuing operations were essentially flat, inching up to $10.6 million from $10.5 million
You may also be interested in...
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.